Literature DB >> 17920794

Preparation and characterization of intravenously injectable nimodipine nanosuspension.

Ruolan Xiong1, Weigen Lu, Jun Li, Peiquan Wang, Rong Xu, Tingting Chen.   

Abstract

The purpose of this study was to develop an alternative, improved and better tolerated injectable nimodipine nanosuspension compared with commercially available ethanol solution. In this study, nimodipine nanosuspension was prepared by high-pressure homogenization (HPH). The effects of the production parameters such as pressure, cycle numbers and crushing principles on the mean particle size, 99% diameter and polydispersity of the nanosuspension were investigated. Characterization of the product was performed by scanning electron microscope (SEM) and differential scanning calorimeter (DSC). The safety of the nimodipine nanosuspension was discussed with special attention to contamination by microparticles and the increase in saturation solubility C(s). Irritability study in rabbits showed that this formulation provided less local irritation and phlebitis risks than the commercial ethanol product, which represented a promising new drug formulation for intravenous therapy of subarachnoid hemorrhage (SAH)-related vasospasm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920794     DOI: 10.1016/j.ijpharm.2007.08.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  14 in total

1.  Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation.

Authors:  Peng Quan; Dengning Xia; Hongze Piao; Hongyu Piao; Kai Shi; Yinnong Jia; Fude Cui
Journal:  AAPS PharmSciTech       Date:  2011-09-03       Impact factor: 3.246

2.  Interaction studies between indomethacin nanocrystals and PEO/PPO copolymer stabilizers.

Authors:  Peng Liu; Tapani Viitala; Alma Kartal-Hodzic; Huamin Liang; Timo Laaksonen; Jouni Hirvonen; Leena Peltonen
Journal:  Pharm Res       Date:  2014-08-22       Impact factor: 4.200

3.  Preparation and in vitro/in vivo evaluation of felodipine nanosuspension.

Authors:  Bhanu P Sahu; Malay K Das
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-11-07       Impact factor: 2.441

4.  Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs.

Authors:  Fei Wang; Yu-hua Yin; Feng Jia; Ji-yao Jiang
Journal:  J Neurotrauma       Date:  2013-04-01       Impact factor: 5.269

5.  Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery.

Authors:  Hassan M Rashed; Rehab N Shamma; Emad B Basalious
Journal:  Drug Deliv       Date:  2016-11       Impact factor: 6.419

6.  Nimodipine-Loaded Pluronic® Block Copolymer Micelles: Preparation, Characterization, In-vitro and In-vivo Studies.

Authors:  Farzaneh Sotoudegan; Mohsen Amini; Mehrdad Faizi; Reza Aboofazeli
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

7.  A Novel Drug Delivery Carrier Comprised of Nimodipine Drug Solution and a Nanoemulsion: Preparation, Characterization, in vitro, and in vivo Studies.

Authors:  Saixu Huang; Zhiyong Huang; Zhiqin Fu; Yamin Shi; Qi Dai; Shuyan Tang; Yongwei Gu; Youfa Xu; Jianming Chen; Xin Wu; Fuzheng Ren
Journal:  Int J Nanomedicine       Date:  2020-02-18

8.  Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study.

Authors:  Xu Song; Yu Jiang; Chunjuan Ren; Xun Sun; Qiang Zhang; Tao Gong; Zhirong Zhang
Journal:  Int J Nanomedicine       Date:  2012-07-13

9.  One-step self-assembled nanomicelles for improving the oral bioavailability of nimodipine.

Authors:  Jing-Wen Luo; Zhi-Rong Zhang; Tao Gong; Yao Fu
Journal:  Int J Nanomedicine       Date:  2016-03-15

Review 10.  Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.

Authors:  Meng Li; Mohammad Azad; Rajesh Davé; Ecevit Bilgili
Journal:  Pharmaceutics       Date:  2016-05-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.